Pilot study: Effect of 3,3′-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer

Nutrition and Cancer

Volumn 50, Issue 2, 2004, Pages 161-167

  Dalessandri, Kathie M ^a,b   Firestone, Gary L ^a   Fitch, Mark D ^d   Bradlow, H Leon ^c   Bjeldanes, Leonard F ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; 3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; 6BETA HYDROXYHYDROCORTISONE; BIORESPONSE DIM; CYTOCHROME P450 3A4; ESTRADIOL; ESTRIOL; ESTRONE; HYDROCORTISONE; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG HYDROXYLATION; DRUG MECHANISM; ESTROGEN URINE LEVEL; FEEDING BEHAVIOR; FEMALE; HORMONE URINE LEVEL; HUMAN; PILOT STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; URINALYSIS;

AGED; BREAST NEOPLASMS; DIETARY SUPPLEMENTS; ESTRADIOL; ESTRIOL; FEMALE; HORMONES; HUMANS; HYDROCORTISONE; HYDROXYESTRONES; INDOLES; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE;

BRASSICA; BRASSICA OLERACEA VAR. BOTRYTIS; BRASSICA OLERACEA VAR. CAPITATA; BRASSICA OLERACEA VAR. GEMMIFERA; HUMAN ECHOVIRUS 1;

EID: 12744269542     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5002_5     Document Type: Article

References (57)

1. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, et al.: Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 130(2S Suppl), 467S-471S, 2000.
2. Arneson DW, Hurwitz A, McMahon LM, and Robaugh D: Presence of 3,3′-Diindolylmethane in human plasma after oral administration of Indole-3-carbinol. Proceedings of the American Association for Cancer Research 40(2833), 1999.
3. Tiwari RK, Guo L, Bradlow HL, Telang NT, and Osborne MP: Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 86, 126-131, 1994.
4. 1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273, 3838-3847, 1998.
5. Cover CM, Hsieh SJ, Cram EJ, Hong C, Riby JE, et al.: Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59, 1244-51, 1999.
6. Firestone GL and Bjeldanes LF: Indole-3-Carbinol and 3-3′- Diindolylmethane anti-proliferative signaling pathways control cell cycle gene transcription in human breast cancer cells by regulating promoter-Sp1 transcription factor interactions. J Nutr 133, 2448S-2455S, 2003.
7. Staub RE, Feng C, Onisko B, Bailey GS, Firestone GL, et al.: Fate of indole-3-carbinol in cultured human breast tumor cells. Chem Res Toxicol 15, 101-9, 2002.
8. Rahman KM, Aranha O, and Sarkar FH: Indole-3-carbinol induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. Nutr Cancer 45, 101-102, 2003.
9. Sarkar FH, Rahman KM, and Li Y: Bax translocation to mitochondria is an important event in inducing apoptotic cell death by indole-3-carbinol (I3C) treatment of breast cancer cells. J Nutr 133(7 Suppl), 2434S-2439S, 2003.
10. Rahman KM, Aranha O, Glazyrin A, Chinni SR, and Sarkar FH: Translocation of Bax to mitochondria induces apoptotic cell death in indole-3-carbinol (I3C) treated breast cancer cells. Oncogene 19, 5764-5771, 2000.
11. Meng Q, Goldberg ID, Rosen EM, and Fan S: Inhibitory effects of indole-3-carbinol on invasion and migration in human breast cancer cells. Breast Cancer Res Treat 63, 147-152, 2000.
12. Hong C, Firestone GL, and Bjeldanes FL: Bcl-2-mediated apoptotic effects of 3,3′-diindolymethane (DIM) in human breast cancer cells. Biochem Pharmacol 63, 1085-109, 2002.
13. Hong C, Kim HA, Firestone GL, and Bjeldanes LF: 3,3prime; Diindolylmethane (DIM) induces a cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21 WAF1/CIP1 expression. Carcinogenesis 23, 1297-1305, 2002.
14. Chen I, McDougal A, Wang F, and Safe S: Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 19, 1631-1639, 1998.
15. Chen I, Safe S, and Bjeldanes L: Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol 51, 1069-1076, 1996.
16. Safe S and McDougal A: Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers. Int J Oncol 20, 1123-1128, 2002.
17. Hestermann EV and Brown M. Agonist and chemopreventive ligands induce differential transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol 23, 7920-7925, 2003.
18. Benabadji SH, Wen R, Zheng JB, Dong XC, and Yuan SG. Anticarcinogenic and antioxicant activity of diindolylmethane derivatives. Acta Pharmacol Sin 25, 666-71, 2004.
19. Leong H, Firestone GL, and Bjeldanes LF: Cytostatic effects of 3,3′-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression. Carcinogenesis 22, 1809-1817, 2001.
20. Leong H, Riby JE, Firestone GL, and Bjeldanes LF: Potent ligand-independent estrogen receptor activation by 3,3′-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways. Mol Endocrinol 18, 291-302, 2004.
21. Le HT, Schaldach CM, Firestone GL, and Bjeldanes LF: Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem 278, 21136-45, 2003.
22. Li Y, Li X, and Sarkar FH: Gene expression profiles of I3C- and DIM-treated PC3 human prostate cancer cells determined by cDNA microarray analysis. J. Nutr 133, 1011-9, 2003.
23. Bradlow HL, Mischnovicz J, Telang NT, and Osborne MP: Effects of dietary indole-3-carbinol, on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12, 1571-1574, 1994.
24. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, and Eto I, et al.: Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 15, 709-16, 1995.
25. Leibelt DA, Hedstrom OR, Fischer KA, Pereira CB, and Williams DE: Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3′-diindolylmethane in sprague-dawley rats. Toxicol Sci 74, 10-21, 2003.
26. Bresnick E, Birt DF, Wolterman K, Wheeler M, and Markin RS: Reduction in mammary tumorigenesis in the rat by cabbage and cabbage residue. Carcinogenesis 11, 1159-1163, 1990.
27. Parkin DR and Malejka-Giganti D: Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3′-diindolylmethane and its parent compound indole-3-carbinol. Cancer Detect Prev 28, 72-9, 2004.
28. Bell MC, Crowley-Nowich P, Bradlow HL, Sepkovic DW, Schmidt-Grimminger D, et al.: Placebo-controlled trial of inole-3 -carbinol in the treatment of CIN. Gynecol Oncol 78, 123-9, 2000.
29. Zeligs MA, Sepkovic DW, Manrique C, Macsalka M, Williams, et al.: Absorption-enhanced 3,3′-diindolylmethane: human use in HPV-related, benign and pre-cancerous conditions (abstr). Proceedings of the American Association for Cancer Research Apr, 42(3198), 2002, p. 644.
30. Auborn KJ: Therapy for recurrent respiratory papillomatosis. Antivir Ther 7, 1-9, 2002.
31. Wiatrak BJ: Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 16, 433-41, 2003.
32. Schneider J, Huh MM, Bradlow HL, and Fishman J: Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259, 4840-4845, 1984.
33. Kall MA, Vang O, and Clausen J: Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 4, 793-9, 1996.
34. Fowke JH, Longcope C, and Hebert JR: Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev, 9, 773-779, 2000.
35. Wong GY, Bradlow HL, Sepkovic D, Mehl S, Mailman J, et al.: Dose-Ranging Study of Indole-3-Carbinol for Breast Cancer Prevention. J Cell Biochem Suppl 28/29, 111-116, 1997.
36. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, et al.: Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 79, 3047-51, 1982.
37. Kabat GC, Chang CJ, Sparano JA, Sepkovic DW, Hu XP, et al.: Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 6, 505-509, 1997.
38. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH, et al.: Urinary 2/16alpha- hydroxyestorne ratio:correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 27, 294-299, 1998
39. Zheng W, Dunning L, Jin F, and Holtzman J: Correspondence re: G.C. Kabat, et al.: Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomark Prev 6, 505-509, 1997.
40. Ursin G, London S, Stanczk FZ, Gentzschein E, Paganini-Hill A, et al.: Urinary 2-hydroxyestrone/16alpha- hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91, 1067-1072, 1999.
41. Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, et al.: Metabolism and risk of breast cancer: a prospective analysis of 2:16 hydroxyestrone ratio and risk of breast cancer in premenopausal and postmenopausal women. Cancer Epidemiol 11, 635-640, 2000.
42. Meilahn EN, DeStavola B, Allen DS, Fentiman I, Bradlow HL, et al.: Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br. J Cancer 78, 1250-1255, 1998.
43. Pasagian-Macauley A, Meilahan EN, Bradlow HL, Sepkovic DW, Buhari AM, et al.: Urinary Markers of Estrogen Metabolism in Premenopausal Women. Steroids 61, 461-461, 1996.
44. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, et al.: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95, 1218-26, 2003.
45. Zheng W, Jin F, Dunning LA, Shu XO, and Dai Q: Epidemiological study of urinary 6-beta-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10, 237-242, 2001.
46. Stresser DM, Blanchard AP, Turner SD, Erve JC, Dandeneau AA, et al.: Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28, 1440-1448, 2000.
47. Lin Y, Anderson GD, Kantor E, Ojemann LM, and Wilensky AJ: Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol be-tween Asian and Caucasian women. J Clin Pharmacol 39, 578-82, 1999.
48. Clarke CA, Glaser SL, West DW, Ereman RR, Erdmann CA, et al.: Breast Cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990-1999. Breast Cancer Res 4, R13, 2002.
49. Taioli E, Bradlow HL, Garbers SV, Sepkovic DW, Osborne MP, et al.: Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 23, 232-237, 1999.
50. Michnovicz JJ, Adlercreutz H, and Bradlow HL: Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst 89, 718-23, 1997.
51. Fenwick GR, Heaney RK, and Mullin WJ: Glucosinolates and their breakdown products in food and food plants. Crit Rev Food Sci Nutr 18, 123-201, 1983.
52. Elfving S: Studies on the naturally occurring goitrogen 5-vinyl-2-thiooxazolidone. Metabolism and antithyroid effect in the rat. Ann Clin Res Suppl 28, 1-41, 1980.
53. Sepkovic DW, Bradlow HL, Michnovicz J, Murtezani S, Levy I, et al.: Catechol estrogen production in rat microsomes after treatment with indole carbinol, ascorbigen, or B-napthaflavone: A camparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. Steroids 59, 318-323, 1994.
54. Klug, TL, Bradlow HL, and Sepkovic DW: Monoclonal antibody based enzyme immunoassay for simultaneous quantitation of 2 and 16α-hydroxyestrone in urine. Steroids 59, 648-655, 1994.
55. Galteau MM and Shamsa F: Urinary 6beta-hydroxycortisol: a valited test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and animals. Eur J Clin Pharmacol 59, 713-33, 2003.
56. Sepkovic DW, Bradlow HL, and Bell M: Quantitative determination of 3,3′-Diindolylmethane in the urine of individuals receiving indole-3-carbinol. Nutr Cancer 41, 57-63, 2002.
57. Bradlow HL and Sepkovic D: Diet and Breast Cancer. Ann NY Acad Sci 963, 247-267, 2002.